

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (MN-235) CALDERASIB

PRONUNCIATION kal der' ah sib


THERAPEUTIC CLAIM Antineoplastic

CHEMICAL NAMES

1,18-Etheno-4*H*-pyrido[4,3-*e*]pyrimido[1,6-*g*][1,4,7,9]benzodioxadiazacyclododecin-4-one, 20-chloro-2-[(2*S*,5*R*)-2,5-dimethyl-4-(1-oxo-2-propen-1-yl)-1-piperaziny]-14,17-difluoro-11,12-dihydro-6-(1-methylethyl)-, (5*S*,17*aR*)-

(5*P*,17*aM*)-20-chloro-2-[(2*S*,5*R*)-2,5-dimethyl-4-(prop-2-enoyl)piperidin-1-yl]-14,17-difluoro-6-(propan-2-yl)-11,12-dihydro-4*H*-1,18-ethenopyrido[4,3-*e*]pyrimido[1,6-*g*][1,4,7,9]benzodioxadiazacyclododecin-4-one

STRUCTURAL FORMULA



MOLECULAR FORMULA  $C_{32}H_{31}ClF_2N_6O_4$

MOLECULAR WEIGHT 637.09

TRADEMARK	None as yet
SPONSOR	Merck Sharp & Dohme LLC
CODE DESIGNATIONS	MK-1084
<u>CAS</u> REGISTRY NUMBER	2641216-67-1
UNII	YQF4ART47C
WHO NUMBER	13789

gbk